| Dena Elizabeth Douglas, RN HNB-BC | |
|
382 W 9th St Ste 8, Ship Bottom, NJ 08008-4634 | |
| (609) 698-1700 | |
| Not Available |
| Full Name | Dena Elizabeth Douglas |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 382 W 9th St Ste 8, Ship Bottom, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285359398 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 26NR16692700 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dena Elizabeth Douglas, RN HNB-BC 9 Pond Hollow Ln, West Creek, NJ 08092-3143 Ph: (609) 833-1269 | Dena Elizabeth Douglas, RN HNB-BC 382 W 9th St Ste 8, Ship Bottom, NJ 08008-4634 Ph: (609) 698-1700 |
News Archive
A protein produced by the central nervous system's support cells seems to play two opposing roles in protecting nerve cells from damage, an animal study by Johns Hopkins researchers suggests: Decreasing its activity seems to trigger support cells to gear up their protective powers, but increasing its activity appears to be key to actually use those powers to defend cells from harm.
An innovative primary care-based asthma program improves identification of poorly controlled asthma among children and enhances treatment plans, compared to care provided during routine office visits, according to research published in the current edition of the Journal of Asthma.
AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).
Viron Therapeutics Inc., a biotechnology company pioneering the development of immune-modulating protein therapeutics derived from pathogens, today reported results from a Phase IIa clinical trial evaluating VT-111 (Serp-1), an anti-inflammatory protein derived from the myxoma virus.
Pfizer Inc. announced today that the United States District Court for the District of Delaware upheld its composition of matter patent and pain and seizure use patents covering LYRICA (pregabalin) capsules CV. With this decision, Pfizer will exclusively provide pregabalin as LYRICA to patients through December 30, 2018 in the U.S., pending generic company appeal and further litigation.
› Verified 7 days ago